The spectrum of cardiovascular disease in children with predialysis chronic kidney disease

Advances in Chronic Kidney Disease

Volumn 11, Issue 3, 2004, Pages 319-327

  Chavers, Blanche M ^a,b   Herzog, Charles A ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

anemia; cardiovascular disease; chronic kidney disease; dyslipidemia; hypertension; Pediatric; risk factors

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; IRON; PERIPHERAL VASODILATING AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 3242697970     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.arrt.2004.04.002     Document Type: Article

References (72)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease Evaluation, classification and stratification. Am J Kidney Dis. 39:(suppl 1):2002;S1-S266
2. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population Third national health and nutrition examination survey. Am J Kidney Dis. 41:2003;1-12
3. Culleton B.F., Larson M.G., Wilson P.W.F., et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 56:1999;2214-2219
4. Levin A., Thompson C.R., Ethier J., et al. Left ventricular mass index increase in early renal disease Impact of decline in hemoglobin. Am J Kidney Dis. 34:1999;125-134
5. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 108:2003;2154-2169
6. Foley R.N., Parfrey P.S., Harnett J.D., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 47:1995;186-192
7. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 32:1998;853-906
8. National Kidney Foundation. K/DOQI clinical practice guidelines on managing dyslipiedmias in chronic kidney disease. Am J Kidney Dis. 41:(suppl 3):2003;S1-S77
9. Chavers B., Schnaper H.W. Risk factors for cardiovascular disease in children on maintenance dialysis. Adv Ren Replacement Ther. 8:2001;180-190
10. Grunbaum J.A., Kann L., Kinchen S.A., et al. Youth risk behavior surveillance - United States, 2001. J Sch Health. 72:2002;313-328
11. U.S. Renal Data System. USRDS 2003 Annual Data Report. Available at: http://www.usrds.org/adr.htm. Accessed February 27:2004
12. Seikaly M.G., Ho P.L., Emmett L., et al. Chronic renal insufficiency in children The 2001 annual report of the NAPRTCS. Pediatr Nephrol. 18:2003;796-804
13. Parekh R.S., Carroll C.E., Wolfe R.A., et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr. 141:2002;191-197
14. Chavers B.M., Li S., Collins A.J., et al. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int. 62:2002;648-653
15. Groothoff J.W., Gruppen M.P., Offringa M., et al. Mortality and causes of death of end-stage renal disease in children A Dutch cohort study. Kidney Int. 61:2002;621-629
16. Anderson R.N., Smith B.L. Deaths Leading Causes for 2001. National Vital Statistics Reports. 52:2003;1-85
17. Mitsnefes M.M., Daniels S.R., Schwartz S.M., et al. Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol. 16:2001;318-323
18. Vakili B.A., Okin P.M., Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J. 141:2001;334-341
19. Silberberg J.S., Barre P.E., Prichard S.S., et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 36:1989;286-290
20. Mitsnefes M.M., Kimball T.R., Witt S.A., et al. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation. 107:2003;864-868
21. Johnstone L.M., Jones C.L., Grigg L.E., et al. Left ventricular abnormalities in children, adolescents and young adults with renal disease. Kidney Int. 50:1996;998-1006
22. Lipshultz S.E., Somers M.J.G., Lipsitz S.R., et al. Serum cardiac troponin and subclinical cardiac status in pediatric chronic renal failure. Pediatrics. 112:2003;79-86
23. O'Regan S., Matina D., Ducharme G., et al. Echocardiographic assessment of cardiac function in children with chronic renal failure. Kidney Int. 24:(suppl):1983;S77-S82
24. Atalay S., Ekim M., Tutar H.E., et al. Systolic and diastolic function in children with chronic renal failure. Pediatr Int. 44:2002;18-23
25. Ulmer H.E., Heupel E.W., Scharer K. Long-term evaluation of cardiac function utilizing systolic time intervals in children with chronic renal failure. Int J Pediatr Neprhrol. 3:1982;79-86
26. Ulmer H.E., Greiner H., Schuler H.W., et al. Cardiovascular impairment and physical working capacity in children with chronic renal failure. Acta Paediatr Scand. 67:1978;43-48
27. Bonzel K.E., Wildi B., Weiss M., et al. Spiroergometric performance of children and adolescents with chronic renal failure. Pediatr Nephrol. 5:1991;22-29
28. U.S. Renal Data System USRDS 2002 Annual Data Report. 2002;. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
29. Bosch A., Ulmer H.E., Keller H.E., et al. Electrocardiographic monitoring in children with chronic renal failure. Pediatr Nephrol. 4:1990;140-144
30. Kocak G., Atalay S., Bakkaloglu S., et al. QT/corrected QT (QTc) intervals and QT/QTc dispersions in children with chronic renal failure. Int J Cardiol. 70:1999;63-67
31. Suzuki R., Tsumura K., Inoue T., et al. QT interval prolongation in the patients receiving maintenance hemodialysis. Clin Nephrol. 49:1998;240-244
32. Jungers P., Massy Z.A., Nguyen K., et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients A prospective study. Nephrol Dial Transplant. 12:1997;2597-2602
33. Jungers P., Khao N., Massy Z.A., et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients A multicentric study in the Ile de France district. Nephrol Dial Transplant. 14:1999;898-902
34. Zieske A.W., Malcom G.R., Strong J.P. Natural history and risk factors of atherosclerosis in children and youth The PDAY study. Pediatr Pathol Mol Med. 21:2002;213-237
35. Strong J.P., Malcon G.T., Mahan G.A., et al. Prevalence and extent of atherosclerosis in adolescents and young adults Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth study. JAMA. 281:1999;727-735
36. Berenson G.S., Srinivasan S.R., Bao W., et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 338:1998;1650-1656
37. Nayir A., Bilge I., Kilicaslan I., et al. Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant. 16:2001;2041-2047
38. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 342:2000;1478-1483
39. Oh J., Wunsch R., Turzer M., et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 106:2002;100-105
40. Groothoff J.W., Gruppen M.P., Offringa M., et al. Increased arterial stiffness in young adults with end-stage renal disease since childhood. J Am Soc Nephrol. 13:2002;2953-2961
41. Scharer K., Schmidt K.G., Soerger M. Cardiac function and structure in patients with chronic renal failure. Pediatr Nephrol. 13:1999;951-965
42. Locatelli F., Pozzoni P., Tentori F., et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant. 18:(suppl):2003;vii2-vii9
43. Sarnak M.J. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis. 41:(suppl):2003;S11-S17
44. Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 356:2000;147-152
45. Cook S., Weitzman M., Auinger P., et al. Prevalence of a metabolic syndrome phenotype in adolescents Findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 157:2003;821-827
46. Steinberger J., Daniels S.R. Obesity, insulin resistance, diabetes, and cardiovascular risk in children. An American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation. 107:2003;1448-1453
47. Williams C.L., Hayman L.L., Daniels S.R., et al. Cardiovascular health in childhood. A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 106:2002;143-160
48. Kari J.A., Donald A.E., Vallance D.T., et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 52:1997;468-472
49. Bennett-Richards K.J., Kattenhorn M., Donald A.E., et al. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int. 62:2002;1372-1378
50. Lilien M., Duran M., Van Hoeck K., et al. Hyperhomocyst (e) inaemia in children with chronic renal failure. Nephrol Dial Transplant. 14:1999;366-368
51. Merouani A.L.M., Delvin E.E., Genest J., et al. Plasma homocysteine concentration in children with chronic renal failure. Pediatr Nephrol. 16:2001;805-811
52. Kang H.G., Lee B.S., Hahn H., et al. Reduction of plasma homocysteine by folic acid in children with chronic renal failure. Pediatr Nephrol. 17:2002;511-514
53. Sebekova K., Podracka L., Heidland A., et al. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation - are they inter-related? Clin Nephrol. 56:(suppl):2001;S21-S26
54. NKF-DOQI Work Group. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 42:(suppl):2003;S10-S201
55. National Heart, Lung, and Blood Institute. Update on the 1987 Task Force on High Blood Pressure in Children and Adolescents A Working Group from the National High Blood Pressure Education Program. Pediatrics. 98:1996;649-658
56. Mitsnefes M., Ho P.-L., McEnery P.T. Hypertension and progression of chronic renal insufficiency in children A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol. 14:2003;2618-2622
57. Wingen A.M., Fabian-Bach C., Schaefer F., et al. Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children European study group of nutritional treatment of chronic renal failure in childhood. Lancet. 349:1997;1117-1123
58. Mitsnefes M.M., Kimball T.R., Daniels S.R. Office and ambulatory blood pressure elevation in children with chronic renal failure. Pediatr Nephrol. 18:2003;145-149
59. Bartosh S.M., Aronson A.J. Childhood hypertension An update on etiology, diagnosis, and treatment. Pediatr Clin North Am. 46:1999;235-252
60. Smith P.S. Management of end-stage renal disease in children. Ann Pharmacother. 32:1998;929-939
61. Franscini L.M.D., Von Vigier R.O., Pfister R., et al. Effectiveness and safety of the angiotensin II antagonist Irbesartan in children with chronic kidney diseases. Am J Hypertens. 15:2002;1057-1063
62. McGonigle R.J., Wallin J.D., Shadduck R.K., et al. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int. 25:1984;437-444
63. NKF-DOQI Work Group. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis. 37:(suppl):2001;S182-S238
64. Chavers B.M., Roberts T.L., Herzog C.A., et al. Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int. 65:2004;266-273
65. Warady B.A., Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol. 18:2003;1055-1062
66. National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 89:1992;525-584
67. Chavers B.M., Hardstedt M., Gillingham K.J. Hyperlipidemia in pediatric kidney transplant recipients treated with cyclosporine. Pediatr Nephrol. 18:2003;565-569
68. Querfeld U., Lang M., Friedrich B., et al. Lipoprotein (a) serum levels and apolipoprotein (a) phenotypes in children with chronic renal disease. Pediatr Res. 34:1993;772-776
69. Querfeld U., Haffner D., Wingen A.M., et al. Treatment with growth hormone increases lipoprotein (a) serum levels in children with chronic renal insufficiency. Eur J Pediatr. 155:1996;913
70. Berger M., James G.P., Davis E.R., et al. Hyperlipidemia in uremic children Response to peritoneal dialysis and hemodialysis. Clin Nephrol. 9:1978;19-24
71. Saland J.M., Ginsberg H., Fisher E.A. Dyslipidemia in pediatric renal disease Epidemiology, pathophysiology, and management. Curr Opin Pediatr. 14:2002;197-204
72. Querfeld U. Should hyperlipidemia in children with the nephrotic syndrome be treated? Pediatr Nephrol. 13:1999;77-84